Precede Biosciences Secures $83.5M in Financing to Scale Next-Gen Precision Diagnostics Platform

Precede Presents ESMO 2025 Data On Liquid Biopsy Platform's Ability to Resolve Target Expression in Small Cell Lung Cancer

2025 ESMO Poster: Comprehensive Epigenomic Profiling of Plasma ctDNA Enables Assessment of Drug Target Expression in SCLC

Predicta Biosciences Raises $23.4M for Precision Oncology

Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases

Precede Presents 2025 ASCO Data Highlighting Its Liquid Biopsy Platform to Reveal Biology Underlying Resistance to ADCs and Radiopharmaceuticals

Precede Presents at 2025 ASCO: Cell-free Chromatin Profiles Enable Mechanisms of Response & Resistance to Breast Cancer

Precede Shows Robust Characterization of Response & Resistance to 177Lu-PSMA-617 in mCRPC by Plasma-based Profiling, 2025 ASCO

Predicta Biosciences Launches its First Molecular Diagnostic Product to Improve the Prognosis of Multiple Myeloma

Precede Presents at AACR 2025: Ability to Resolve Gene Expression for Tumor-Specific Genes from a Simple Blood Test

2025 AACR Poster: Robust Prediction of Gene Expression Using Epigenomic Profiling of Plasma cfDNA

Nextpoint Highlights Antibody Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings at AACR

2025 ASCO GU Poster: Epigenomic Profiling of Circulating Chromatin for Detection and Monitoring of Neuroendocrine Prostate Cancer

Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test

2024 SABCS Poster: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy